A DEL-licensed, “picks-and-shovels” psychedelic drug manufacturer whose upside is global supply leadership—but whose survival and valuation hinge on a successful Nasdaq raise and continued regulatory thaw.
Overview
Optimi Health is a vertically integrated psychedelic-pharma manufacturer headquartered in Vancouver with two GMP-compliant facilities in Princeton, BC, and a Health Canada Drug Establishment License enabling production and export of finished psychedelic drug products. It focuses on natural (botanical) psilocybin and synthetic MDMA for regulated therapeutic use, supplying clinicians and researchers—particularly in Australia and Canada—while also operating analytical testing services and a functional mushroom wellness brand. Its differentiation versus peers is tangible manufacturing scale, regulatory licensing, and early ability to export into Australia’s rescheduled framework. The company’s credibility is strengthened by insider alignment and the Wilson family’s involvement. However, revenues remain very small and losses large, making near-term financing (Nasdaq uplist/IPO) central to the investment case.